Caption Management’s Roivant Sciences ROIV Stock Holding History

Caption Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-157,600	Closed	-$1.82M	–	1785
2024 Q3	$1.82M	Buy	+157,600	New	+$1.79M	0.03%	596

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caption Management's ROIV Position: Q1 2026 in Review

Caption Management increased its Roivant Sciences (ROIV) stake by 37% in Q1 2026, buying an estimated $1.51M and bringing the position to 219,800 shares worth $6.09M. The position accounts for 0.04% of the portfolio, ranked #475.

Caption Management first reported a position in ROIV in Q3 2023 and has held it in 8 quarters since. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Caption Management held 219,800 shares of Roivant Sciences worth $6.09M as of Q1 2026.
Caption Management bought 58,813 Roivant Sciences shares in Q1 2026, an estimated $1.51M.
Roivant Sciences made up 0.04% of Caption Management's portfolio in Q1 2026, its #475 holding.
Caption Management first reported a position in Roivant Sciences in Q3 2023 and has held it in 8 quarters since.
439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.